Abstract:
Glutargin" was first introduced into clinical practice in 1996, but widespread therapeutic use began
after 2003, when the clinical efficacy of the drug was confirmed in practice.
Summarizing the results of the analysis of the daily dependence of hepatoprotective activity of
arginine glutamate on prooxidant-antioxidant imbalance, the course of metabolic, excretory and
detoxification processes in acute paracetamol hepatitis established periods of the day when the drug is
most pronounced hepatitis. It was found that the most significant positive changes in prooxidantantioxidant imbalance with glutargine were observed under conditions of its use against the
background of night and day simulations of hepatitis, which is confirmed by the most pronounced
increase in reduced glutathione (18-32%) and decrease in thiobarbituric acid %). It was investigated that
in the night and day periods under the action of arginine glutamate the most pronounced daily
decrease in the activity of cytolysis markers was observed, while in the morning and evening only the
tendency to decrease was registered. It was found that the most pronounced tendency to normalize
the glycogen content of arginine glutamate was observed against the background of modeling
hepatitis at night. It was investigated that under the influence of arginine glutamate an increase in urea
content by 10-34% was observed in all study periods of the day.
Thus, based on the chronopharmacological preclinical study of the daily dependence of
hepatoprotective properties of arginine glutamate, the most pronounced effect of the drug on the
integrated effect on the study of the system and the exchange for its use at night and day.
